PARP Inhibitor Approved by FDA for Breast Cancer Patients with BRCA Gene Mutation
- Posted by ISPE Boston
- On January 18, 2018
The FDA has expanded the approved use of AstraZeneca’s Lynparza to include the treatment of patients with certain types of breast cancer that have spread and whose tumors have a specific inherited genetic mutation. This makes Lynparza the first PARP inhibitor to be approved for breast cancer; and the first time any drug has been […]
Read More